

Supplementary Material

Elevated levels of cerebrospinal fluid soluble triggering receptor expressed on myeloid cells 2 in multiple system atrophy: a marker of disease-associated microglial activation

Authors: Toshiki Maeda, Yasuaki Mizutani, Reiko Ohdake, Ryunosuke Nagao, Kazuya Kawabata, Sayuri Shima, Akihiro Ueda, Mizuki Ito, Hirohisa Watanabe*

Department of Neurology, Fujita Health University School of Medicine, Toyoake,
Aichi, Japan

*Corresponding author:

Dr. Hirohisa Watanabe, Department of Neurology, Fujita Health University School of
Medicine, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi 470-1192, Japan
Tel: +81-562-93-9295; Fax: +81-562-93-1856

This PDF file includes Fig. S1.




Fig. S1. Comparison of CSF sTREM2 levels in control and patients within one year of disease onset. Comparison of CSF sTREM2 levels among the control, PD, PSP/CBS, and MSA groups, with patient groups restricted to those within one year of disease onset. Data are presented as means $\pm$ standard deviations. Significance was tested using one-way analysis of variance followed by Tukey's post-hoc test. CSF, cerebrospinal fluid; sTREM2, soluble triggering receptor expressed on myeloid cells 2; PD, Parkinson's disease; PSP, progressive supranuclear palsy; CBS, corticobasal syndrome; MSA, multiple system atrophy.